Abstract 413P
Background
To study of immunohistochemical markers of proliferation and apoptosis are important prognostic indicators for predicting the clinical course of tumours and the development of therapeutic tactics.
Methods
The p53 suppressor gene, the bcl-2 oncogene and the Ki-67 antigen are responsible for DNA repair, cell division and apoptosis. In all patients, tumour material was obtained using biopsies and operations. In tumour tissue samples fixed by neutral formalin with standard wiring and embedded in paraffin, tumour markers of apoptosis and proliferation were determined - p53, bcl-2, Ki – 67. A positive result was the presence of specific brown staining of the nuclei in the detection of the Ki-67 antigen and the p53 gene suppressor and the cytoplasm in the detection of the expression of bCl-2.
Results
Cases where the nucleus or cytoplasm was not stained by reaction with antibodies to p53, Ki-67 and bcl-2 or the number of positive cells was less than 10%, the reaction was considered negative (0). Weak (1+) reaction was considered when staining 10-30% of cells; medium reaction (2+) - when staining 30-50% of cells; strong reaction (3+) - intense staining from 70 or more cells. We carried out a comparative assessment of the effectiveness of treatment of patients depending on the type of therapy and the phenotype of tumour cells. Among patients who received systemic chemotherapy, the full effect was observed in 13% of patients. With negative and weakly positive reactions to the mutant p53 gene and Ki 67 among them was 70.6%, and with moderate and strong expression of bcl-2 (80%). Patients with a phenotype of tumour cells with a negative or weakly positive IHC response to the mutant p53 gene (58.5% of patients), weakly positive expression of Ki 67 (70.6% of patients), and high expression of bcl-2 (46.4 % of patients). In 37.4% of patients from this group, the effect of therapy was negative, most of them had tumour cells with high expression of the mutant p53 and Ki 67 gene, and no expression of bcl-2.
Conclusions
It was established that with positive expression of p53 + Ki-67 + and negative bcl-2 parameters, patients had an unfavourable prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ronc.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study
Presenter: Joo-hyun Park
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
60P - Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Presenter: Azhar Rashid
Session: Poster display session
Resources:
Abstract